Money Talks: The Market Forces Behind TAVR’s Coverage Overhaul
The clinical questions surrounding TAVR — heart teams, evidence development, patient selection, and long-term outcomes — appropriately receive substantial attention. But the policy conversation also has an important market dimension.…
